Show results for
Refine by
Pharmaceutical Packaging Industry Equipment Supplied In Poland
7 equipment items found
Manufactured by:Adamus S.A. based inSzczecin, POLAND
With the appropriate design software and production based on digitally controlled machines, we also offer punches and dies with more complex shapes than those typically used in the pharmaceutical ...
Distributed by:ANWIL - ORLEN GROUP based inWłocławek, POLAND
Soda Lye is manufactured under the license of the German company "UHDE GmbH" (membrane method). Sodium hydroxide is one of the basic chemical raw materials and it is used in nearly all branches of industry. It is used as raw material (sodium carrier) in a variety of syntheses in the production of surface active ionic agents, in pharmaceutical industry (in the production of aspirin, salicylic ...
Manufactured by:IKA-Werke GmbH & Co. KG based inStaufen, GERMANY
The ULTRA-TURRAX® UTS is a high-performance dispersing machine for the production of emulsions and suspensions in batch operations. Using the rotor-stator principle, the UTS is best suited for applications that cannot be accomplished using conventional stirring methods. The UTS machine is capable of processing highly abrasive products and media with a viscosity of up to 5.000 mPas. The UTS ...
Manufactured by:Inwet S.A based inChorzów, POLAND
Efficiency: 1kg/h – 5t/h. Frequency: 50 Hz. ...
Manufactured by:SYMBASE S.A. based inRobakowo, POLAND
Tartaric acid has three types of isomers: L(+)-tartaric acid, D(-)-tartaric acid and meso-tartaric acid. A racemic mixture containing 50% L(+)-tartaric acid and 50% D(-)-tartaric acid can be created by a simple organic synthesis process. L(+)-tartaric acid is a natural chemical compound found in many plants, including grapes and ...
by:Pure Biologics SA based inWroclaw, POLAND
Myasthenia gravis (MG) is an autoimmune condition classified as a rare disease. Accordingly, myasthenic patients lack effective treatment options, as this rare disease is not a primary interest of the pharmaceutical industry. However, considerable social and institutional support exists for the development of new therapies to treat rare diseases. The PB005 (AptaMG) project aims to develop a novel ...
by:Pure Biologics SA based inWroclaw, POLAND
Neuromyelitis optica (NMO) is an neurological autoimmune condition classified as a rare disease. Because of this classification, NMO lacks effective treatment options, since it is not of primary interest to the pharmaceutical industry. However, considerable social and institutional support exists for developing new therapies for such rare diseases. The PB002 (AptaPheresis) project aims to ...